FDA Warns Roche On Xeloda Promotion; Agency Is Keeping Close Eye On Drug
Executive Summary
FDA is directing Roche to conduct a broad corrective campaign for the chemotherapy agent Xeloda (capecitabine)
You may also be interested in...
Roche Will Challenge Amgen In U.S. EPO Market; Oncology Business Growing
Roche expects to enter the U.S. EPO market with the continuous erythropoetin receptor activator R-744, Global Pharmaceuticals Head William Burns told securities analysts during a July 23 meeting in Zurich
Roche Will Challenge Amgen In U.S. EPO Market; Oncology Business Growing
Roche expects to enter the U.S. EPO market with the continuous erythropoetin receptor activator R-744, Global Pharmaceuticals Head William Burns told securities analysts during a July 23 meeting in Zurich
DTC Guidance Is High Priority In First Amendment Review, FDA Says
Direct-to-consumer ads are likely to be addressed by FDA early in the upcoming series of First Amendment guidances, Associate Deputy Chief Counsel Seth Ray said during the Food & Drug Law Institute Annual Education Conference in Washington, D.C. April 2